Andrew S. Robertson

Learn More
The need for new drugs and vaccines for neglected tropical diseases (NTDs) is widely accepted [1]. Yet, encouraging pharmaceutical and biotechnology company investment in developing these much-needed treatments remains a challenge due to a lack of a commercial market driving companies to pursue NTD projects [2]. To address this challenge, economists Ridley,(More)
Diseases such as trypanosomiasis, leish-maniasis, and lymphatic filariasis impose substantial health burdens in developing countries [1,2]. These diseases are widely neglected because there is little financial incentive for biopharmaceutical companies to invest in developing new treatments , vaccines, and diagnostics. Most of the 1,000,000,000 people(More)
  • 1